217 related articles for article (PubMed ID: 32056873)
1. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
Jacobsen P; Zhong W; Xu R; Nomikos G
J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
[TBL] [Abstract][Full Text] [Related]
2. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study.
Thase ME; Jacobsen PL; Hanson E; Xu R; Tolkoff M; Murthy NV
J Affect Disord; 2022 Apr; 303():123-130. PubMed ID: 35131363
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.
Mattingly GW; Necking O; Schmidt SN; Reines E; Ren H
Curr Med Res Opin; 2023 Apr; 39(4):613-619. PubMed ID: 36884024
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
[TBL] [Abstract][Full Text] [Related]
5. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
Inoue T; Nishimura A; Sasai K; Kitagawa T
Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR
Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Boulenger JP; Loft H; Olsen CK
Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
Thase ME; Mahableshwarkar AR; Dragheim M; Loft H; Vieta E
Eur Neuropsychopharmacol; 2016 Jun; 26(6):979-93. PubMed ID: 27139079
[TBL] [Abstract][Full Text] [Related]
11. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma.
Christensen MC; Florea I; Loft H; McIntyre RS
J Affect Disord; 2020 Feb; 263():258-266. PubMed ID: 31818787
[TBL] [Abstract][Full Text] [Related]
17. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
[TBL] [Abstract][Full Text] [Related]
19. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
Berhan A; Barker A
BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
[TBL] [Abstract][Full Text] [Related]
20. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study.
Durgam S; Chen C; Migliore R; Prakash C; Thase ME
Depress Anxiety; 2019 Mar; 36(3):225-234. PubMed ID: 30675739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]